Anti-Coagulants - Eastern Asia

Eastern Asia

The Anti-Coagulants market in Eastern Asia is expected to experience significant growth.
By 2024, the revenue in this market is projected to reach US$5.49bn.
Furthermore, a steady annual growth rate (CAGR 2024-2028) of 8.15% is anticipated, leading to a market volume of US$7.51bn by 2028.
In terms of global comparison, United States is expected to generate the highest revenue of US$16,740.00m in 2024.
In Eastern Asia, the demand for novel oral anti-coagulants is rising due to an aging population and increasing prevalence of cardiovascular diseases.

Key regions: Germany, South Korea, France, United States, United Kingdom

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for anti-coagulants in Eastern Asia has been steadily increasing in recent years.

Customer preferences: One of the main drivers of this trend is the aging population in the region, which has led to a higher incidence of cardiovascular diseases and strokes. As a result, there is a growing need for anti-coagulant medications to prevent blood clots and reduce the risk of these conditions.

Trends in the market: Japan is the largest market for anti-coagulants in Eastern Asia, accounting for a significant share of the overall demand. This is due to the country's aging population and high prevalence of cardiovascular diseases. In addition, there has been a shift towards newer, more expensive anti-coagulant drugs that offer improved efficacy and safety profiles compared to traditional therapies.China is also a key market for anti-coagulants in the region, with a rapidly growing demand driven by increasing incidence of cardiovascular diseases and strokes. However, the market in China is highly fragmented, with a large number of domestic and international players competing for market share.

Local special circumstances: South Korea is another important market for anti-coagulants in the region, with a significant demand for newer drugs such as direct oral anticoagulants (DOACs). This is due to the country's high incidence of atrial fibrillation and stroke, as well as a growing awareness of the benefits of DOACs over traditional therapies.

Underlying macroeconomic factors: Overall, the anti-coagulants market in Eastern Asia is expected to continue growing in the coming years, driven by the aging population and increasing incidence of cardiovascular diseases. However, the market is also facing challenges such as rising healthcare costs and regulatory hurdles, which could impact the growth potential of certain products and companies.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.